HWP
ALNY icon

Highline Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Highline Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.42K Buy
18
+2
+13% +$603 ﹤0.01% 837
2026
Q1 		$5.29K Buy
16
+8
+100% +$2.72K ﹤0.01% 711
2025
Q4 		$3.18K Hold
8
– – ﹤0.01% 708
2025
Q3 		$3.65K Buy
8
+1
+14% +$407 ﹤0.01% 678
2025
Q2 		$2.28K Buy
7
+3
+75% +$830 ﹤0.01% 615
2025
Q1 		$1.08K Buy
4
+1
+33% +$257 ﹤0.01% 733
2024
Q4 		$706 Buy
+3
New +$789 ﹤0.01% 559

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Highline Wealth Partners's ALNY Position: Q2 2026 in Review

Highline Wealth Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q2 2026, buying an estimated $603 and bringing the position to 18 shares worth $5.42K. The position accounts for ﹤0.01% of the portfolio, ranked #837.

Highline Wealth Partners first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Highline Wealth Partners held 18 shares of Alnylam Pharmaceuticals worth $5.42K as of Q2 2026.
  • Highline Wealth Partners bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Highline Wealth Partners's portfolio in Q2 2026, its #837 holding.
  • Highline Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Highline Wealth Partners's 13F filing for Q2 2026, filed 15 Jul 2026.